- Home
- ACAD vs TGNA Comparison
ACAD vs TGNA Comparison
Compare ACAD & TGNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- TGNA
- Stock Information
- Founded
- ACAD 1993
- TGNA 1906
- Country
- ACAD United States
- TGNA United States
- Employees
- ACAD N/A
- TGNA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- TGNA Broadcasting
- Sector
- ACAD Health Care
- TGNA Industrials
- Exchange
- ACAD Nasdaq
- TGNA Nasdaq
- Market Cap
- ACAD 2.5B
- TGNA 2.7B
- IPO Year
- ACAD 2004
- TGNA N/A
- Fundamental
- Price
- ACAD $22.71
- TGNA $16.65
- Analyst Decision
- ACAD Buy
- TGNA Strong Buy
- Analyst Count
- ACAD 16
- TGNA 4
- Target Price
- ACAD $27.00
- TGNA $20.50
- AVG Volume (30 Days)
- ACAD 1.6M
- TGNA 1.3M
- Earning Date
- ACAD 08-05-2025
- TGNA 08-06-2025
- Dividend Yield
- ACAD N/A
- TGNA 3.00%
- EPS Growth
- ACAD N/A
- TGNA N/A
- EPS
- ACAD 1.37
- TGNA 2.83
- Revenue
- ACAD $996,283,000.00
- TGNA $3,067,768,000.00
- Revenue This Year
- ACAD $13.39
- TGNA N/A
- Revenue Next Year
- ACAD $10.59
- TGNA $12.30
- P/E Ratio
- ACAD $16.65
- TGNA $5.90
- Revenue Growth
- ACAD 22.42
- TGNA 6.34
- 52 Week Low
- ACAD $13.40
- TGNA $12.76
- 52 Week High
- ACAD $25.23
- TGNA $19.62
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- TGNA 49.74
- Support Level
- ACAD $21.35
- TGNA $16.24
- Resistance Level
- ACAD $22.69
- TGNA $16.82
- Average True Range (ATR)
- ACAD 0.76
- TGNA 0.40
- MACD
- ACAD -0.13
- TGNA -0.00
- Stochastic Oscillator
- ACAD 70.76
- TGNA 58.93
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About TGNA TEGNA Inc
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.